Tianjin Genstar Vaccine

Tianjin Genstar Vaccine Technology is a biotechnology company based in Tianjin, China, specializing in the research, development, and manufacturing of innovative vaccines. As a subsidiary of the GenScript Biotech Group, the company leverages advanced platforms such as recombinant protein expression in Sf9 insect cells and mRNA technology to address global infectious disease challenges. Its primary focus has been the development of a recombinant COVID-19 vaccine, which has successfully progressed through clinical trial stages. The company benefits from the integrated R&D and large-scale production capabilities of its parent organization, aiming to provide high-quality and scalable vaccine solutions. Tianjin Genstar Vaccine represents a strategic expansion of the GenScript ecosystem into the prophylactic biopharmaceutical market.